Pfizer Inc (PFE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and vaccine markets.
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
Here’s Why Pfizer Inc. (PFE) Is Among the Best Dividend Stocks Under $30
Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...
Pfizer beats Q4, FY '24 earnings estimates, stock down slightly in premarket trading
Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...
Pfizer Q4 Results Beat Market; Confirms FY25 Outlook - Update
Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...
Pfizer (NYSE:PFE) Price Target Cut to $29.00 by Analysts at Citigroup
Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...
Pfizer Rises on Q4 Earnings Beat, 2025 Outlook Reaffirmed
Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...
Joplin Globe20h
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance (5) provided on December 17, 2024.